Resident Company News

In a memo delivered last week to all members of the state Legislature, the board members are urging action by this fall on the $347 million project. They wrote the effort is “vital to the entire state, especially its business and research communities, for many...

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study. "Cologuard is a groundbreaking innovation in non-invasive cancer detection. Next-generation Cologuard will set a new performance standard," said Kevin Conroy, chairman and CEO...

Loading new posts...
No more posts